Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.

Abstract:

:Adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) have proven highly effective in rapidly proliferating breast cancer (RPBC). It has also been seen that sequential administration of doxorubicin and CMF is superior to their alternation, especially in indolent tumors. In a phase III study, we evaluated whether adjuvant epirubicin (E) followed by CMF is superior to the inverse sequence in RPBC. Patients with node-negative or 1-3 node-positive RPBC (Thymidine Labeling Index > 3% or histological grade 3 or S-phase > 10% or Ki67 > 20%) were randomized to receive E (100 mg/m(2) i.v. d1, q21 days for 4 cycles) followed by CMF (600, 40, 600 mg/m(2) i.v. d1 and 8, q28 days for 4 cycles) (E → CMF) or CMF followed by E (CMF → E) or CMF for 6 cycles. From November 1997 to December 2004, 1066 patients were enrolled: E → CMF 440, CMF → E 438, and CMF 188. At a median follow-up of 69 months, 5-year OS was 91% (95% CI 88-94) for E → CMF and 93% (95% CI 90-95) for CMF → E, with adjusted hazard ratio of 0.88 (95% CI 0.58-1.35), and DFS was 80% in both arms, with adjusted hazard ratio of 0.99 (95% CI 0.73-1.33, Cox model). Adverse events were similar, apart from a higher rate of neutropenia in the CMF → E arm. No important differences in clinical outcome were observed between the two different sequences, making both a valid option in early breast cancer. Further molecular characterization of the tumors might help to identify subgroups achieving higher benefit from either sequence.

authors

Amadori D,Silvestrini R,De Lena M,Boccardo F,Rocca A,Scarpi E,Schittulli F,Brandi M,Maltoni R,Serra P,Ponzone R,Biglia N,Gianni L,Tienghi A,Valerio MR,Bonginelli P,Amaducci L,Faedi M,Baldini E,Paradiso A

doi

10.1007/s10549-010-1257-5

subject

Has Abstract

pub_date

2011-02-01 00:00:00

pages

775-84

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

125

pub_type

杂志文章,随机对照试验
  • Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.

    abstract::Abnormal translation of mRNAs frequently occurring during carcinogenesis is among the mechanisms that can affect the expression of proteins involved in tumor development and progression. Eukaryotic initiation factor eIF4E is a key regulator of translation of many cancer-related transcripts and its expression is altere...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2671-2

    authors: Heikkinen T,Korpela T,Fagerholm R,Khan S,Aittomäki K,Heikkilä P,Blomqvist C,Carpén O,Nevanlinna H

    更新日期:2013-08-01 00:00:00

  • Obesity, physical activity, and breast cancer survival among older breast cancer survivors in the Cancer Prevention Study-II Nutrition Cohort.

    abstract:PURPOSE:Nearly half of the 3.5 million female breast cancer survivors in the US are aged 65 years or older at diagnosis, yet little is known about associations of obesity and physical activity with breast cancer-specific mortality (BCSM) among older survivors. METHODS:Between 1992 and 2013, 5254 women in the Cancer Pr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4470-7

    authors: Maliniak ML,Patel AV,McCullough ML,Campbell PT,Leach CR,Gapstur SM,Gaudet MM

    更新日期:2018-01-01 00:00:00

  • Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells.

    abstract::We have compared the effects of the progestin R5020 and the antiprogestin RU486 on the growth of the MCF-7 and T47D breast cancer cell lines. Differences between the two compounds were demonstrated in several parameters. 1. Estradiol was required for the efficient inhibition of cell growth of both lines by R5020 but n...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806133

    authors: Gill PG,Vignon F,Bardon S,Derocq D,Rochefort H

    更新日期:1987-10-01 00:00:00

  • Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs.

    abstract::Mammosphere culture has been used widely for the enrichment of mammary epithelial stem cells and breast cancer stem cells (CSCs). Epithelial-to-mesenchymal transition (EMT) also induces stem cell features in normal and transformed mammary cells. We examined whether mammosphere culture conditions per se induced EMT in ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1534-y

    authors: Guttilla IK,Phoenix KN,Hong X,Tirnauer JS,Claffey KP,White BA

    更新日期:2012-02-01 00:00:00

  • SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy.

    abstract::It is unclear which patients with breast cancer benefit from anthracycline-based neoadjuvant chemotherapy and whether taxanes increase survival. Hsp70 and serpinB3 inhibit a lysosomal cell death pathway induced in anthracycline and taxane treated cells, which may be critical for breast cancer cell survival. Thus we ev...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1625-9

    authors: Collie-Duguid ES,Sweeney K,Stewart KN,Miller ID,Smyth E,Heys SD

    更新日期:2012-04-01 00:00:00

  • XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects.

    abstract::Published data on the association between Xeroderma Pigmentosum complementation group D (XPD) Lys751Gln polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association be...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-010-0813-3

    authors: Qiu LX,Yao L,Zhang J,Zhu XD,Zhao XM,Xue K,Mao C,Chen B,Zhan P,Yuan H,Hu XC

    更新日期:2010-11-01 00:00:00

  • The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.

    abstract:INTRODUCTION:Long-term endocrine therapy for breast cancer may have clinical implications as drugs that potentially alter the lipid profile may increase the risk of developing cardiovascular disease. In this study, a companion sub-protocol to the TEAM (Tamoxifen and Exemestane Adjuvant Multicenter) International trial,...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-005-3783-0

    authors: Markopoulos C,Polychronis A,Zobolas V,Xepapadakis G,Papadiamantis J,Koukouras D,Lappas H,Gogas H

    更新日期:2005-09-01 00:00:00

  • Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.

    abstract::In the context of neoadjuvant therapy (NT) for breast cancer patients, different targeted therapy approaches are currently evaluated in clinical trials. Serum markers could help to monitor and optimize such treatment strategies. We investigated human epidermal growth factor receptor 2 serum (sHER2) levels in 175 breas...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-010-1030-9

    authors: Witzel I,Loibl S,von Minckwitz G,Mundhenke C,Huober J,Hanusch C,Henschen S,Hauschild M,Lantzsch T,Tesch H,Latos K,Just M,Hilfrich J,Barinoff J,Eulenburg CZ,Roller M,Untch M,Müller V

    更新日期:2010-09-01 00:00:00

  • Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer.

    abstract:PURPOSE:Time to surgery (TTS) is a potentially modifiable factor associated with survival after breast cancer diagnosis and can serve as a proxy for quality of oncologic care coordination. We sought to determine whether factors associated with delays in TTS vary between patients who receive neoadjuvant systemic therapy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-06012-7

    authors: Prakash I,Thomas SM,Greenup RA,Plichta JK,Rosenberger LH,Hyslop T,Fayanju OM

    更新日期:2020-11-18 00:00:00

  • Vascular proliferation is a prognostic factor in breast cancer.

    abstract::Angiogenesis is important for the growth and spread of malignant tumors, and anti-angiogenesis treatment is currently being evaluated for breast cancer and other tumors. Although microvessel density is the most commonly used tissue-based marker of tumor associated angiogenesis, it has significant limitations and has n...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1785-7

    authors: Arnes JB,Stefansson IM,Straume O,Baak JP,Lønning PE,Foulkes WD,Akslen LA

    更新日期:2012-06-01 00:00:00

  • Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS).

    abstract::Whether wide excision with margins ≥1 cm is sufficient treatment for small low- or intermediate-grade ductal carcinoma in situ (DCIS) is unclear. This is an updated analysis of a phase II, single-arm, prospective trial testing this hypothesis. A total of 158 patients with low- or intermediate-grade DCIS who underwent ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2813-6

    authors: Wong JS,Chen YH,Gadd MA,Gelman R,Lester SC,Schnitt SJ,Sgroi DC,Silver BJ,Smith BL,Troyan SL,Harris JR

    更新日期:2014-01-01 00:00:00

  • Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome.

    abstract:BACKGROUND:We report a novel BRCA1 LGR, involving the complete duplication of exon 3, in an Italian patient with a strong family history of breast and ovarian cancer. Our purpose is to provide an effective characterization of this LGR using a combination of different methods able to establish the exact breakpoints of t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4275-8

    authors: Concolino P,Rizza R,Hackmann K,Paris I,Minucci A,De Paolis E,Scambia G,Zuppi C,Schrock E,Capoluongo E

    更新日期:2017-07-01 00:00:00

  • Phosphocitrate inhibits calcium hydroxyapatite induced mitogenesis and upregulation of matrix metalloproteinase-1, interleukin-1beta and cyclooxygenase-2 mRNA in human breast cancer cell lines.

    abstract::Microcalcifications containing calcium hydroxyapatite (HA) are often associated with malignant human breast lesions. Frequently, they are the only mammographic features that indicate the presence of a tumoural lesion. We previously reported the induction of both mitogenesis and prostaglandin E2 (PGE2) production and t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1023908307108

    authors: Cooke MM,McCarthy GM,Sallis JD,Morgan MP

    更新日期:2003-05-01 00:00:00

  • Incidence of an estrogen receptor polymorphism in breast cancer patients.

    abstract::We previously identified a polymorphism in the human estrogen receptor (ER) gene, within the coding region for the protein's amino terminal B-domain. In estrogen receptor-positive (ER+) breast tumors, the variant allele was preferentially associated with lower levels of ER, and was clinically correlated with frequent ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01980941

    authors: Schmutzler RK,Sanchez M,Lehrer S,Chaparro CA,Phillips C,Rabin J,Schachter B

    更新日期:1991-10-01 00:00:00

  • EpCAM expression is an indicator of recurrence in basal-like breast cancer.

    abstract::Advances in the understanding of the molecular basis of breast cancer have necessitated a definition of more sensitive and specific indicators of prognosis that are central to the underlying cancer biology and that reflect the complicated and heterogeneous nature of the disease. This study investigates the expression ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1813-7

    authors: Agboola AJ,Paish EC,Rakha EA,Powe DG,Macmillan RD,Ellis IO,Green AR

    更新日期:2012-06-01 00:00:00

  • G:C > A:T mutations and potential epigenetic regulation of p53 in breast cancer.

    abstract::Analysis of germline p53 mutations in breast cancer reveals that the Li-Fraumeni and Li-Fraumeni-like syndromes are mostly related to the loss of initiation codon 133 of regulatory TP53 isoforms (Delta133p53). In eight codons of exons 5-8 (including 133), mutations are frequent in Li-Fraumeni-related, but scarce in sp...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9514-y

    authors: Kouidou S,Malousi A,Kyventidis A,Fragou A,Maglaveras N

    更新日期:2007-12-01 00:00:00

  • (-)-Epigallocatechin (EGC) of green tea induces apoptosis of human breast cancer cells but not of their normal counterparts.

    abstract::(-)-Epigallocatechin (EGC), one of green tea polyphenols, has been shown to inhibit growth of cancer cells. However its mechanism of action is poorly known. We show here that EGC strongly inhibited the growth of breast cancer cell lines (MCF-7 and MDA-MB-231) but not that of normal breast epithelial cells. The inhibit...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1020833410523

    authors: Vergote D,Cren-Olivé C,Chopin V,Toillon RA,Rolando C,Hondermarck H,Le Bourhis X

    更新日期:2002-12-01 00:00:00

  • Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.

    abstract::BRCAness breast tumors represent a group of sporadic tumors characterized by a reduction in BRCA1 gene expression. As BRCA1 is involved in double-strand breaks (DSBs) repair, dysfunctional BRCA pathway could make a tumor sensitive to DNA damaging drugs (e.g., platinum agents). Thus, accurately identifying BRCAness cou...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3648-0

    authors: Branham MT,Campoy E,Laurito S,Branham R,Urrutia G,Orozco J,Gago F,Urrutia R,Roqué M

    更新日期:2016-01-01 00:00:00

  • Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread.

    abstract::The early spread of tumor cells in primary breast cancer patients may occur either through lymphatic or hematogenous dissemination. Lymph node (LN) status and presence of disseminated tumor cells (DTC) in bone marrow (BM) are independent predictors of poor outcome. It is unknown which factors determine one or the othe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1802-x

    authors: Hartkopf AD,Banys M,Krawczyk N,Staebler A,Becker S,Hoffmann J,Hahn M,Wallwiener M,Fehm T

    更新日期:2012-01-01 00:00:00

  • Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study.

    abstract::Estrogen receptor (ER)-positive/progesterone receptor (PR)-positive invasive ductal carcinoma accounts for ~45 % of invasive breast cancer (BC) diagnoses in the U.S. Despite reductions in BC mortality attributable to mammography screening and adjuvant hormonal therapy, an important challenge remains the development of...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3554-5

    authors: Buas MF,Rho JH,Chai X,Zhang Y,Lampe PD,Li CI

    更新日期:2015-09-01 00:00:00

  • The immune system response during development and progression of carcinogen-induced rat mammary tumors: prevention of tumor growth and restoration of immune system responsiveness by thymopentin.

    abstract::A detailed analysis of the immune system response has been performed during the development and progression of dimethylbenz(a)anthracene (DMBA)-induced rat mammary tumors. For this aim, a number of immune parameters (thymocyte and splenocyte proliferative response to T-dependent mitogens, antibody production, lymphocy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00665692

    authors: Gallo F,Morale MC,Sambataro D,Farinella Z,Scapagnini U,Marchetti B

    更新日期:1993-09-01 00:00:00

  • Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.

    abstract::Familial aggregations of breast/ovarian cancer cases frequently depend on BRCA1/2 pathogenic mutations. Here we counselled 120 Italian breast/ovarian cancer families and selected 73 probands for BRCA1/2 mutation screening. Through this analysis we defined the prevalence of BRCA1/2 pathogenic mutations occurring in Ita...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9225-9

    authors: Giannini G,Capalbo C,Ristori E,Ricevuto E,Sidoni T,Buffone A,Cortesi E,Marchetti P,Scambia G,Tomao S,Rinaldi C,Zani M,Ferraro S,Frati L,Screpanti I,Gulino A

    更新日期:2006-11-01 00:00:00

  • Growth inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by controlled-release low-dose medroxyprogesterone acetate.

    abstract::Since our previous findings had indicated that the androgenic steroid medroxyprogesterone acetate (MPA) exerts potent inhibitory effects on 7,12-dimethylbenz(a)anthracene (DMBA)-induced tumor growth, we have studied the effect of low doses of MPA released from Depo-Provera and from 50:50 poly[DL-lactide-co-glycolide] ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01961245

    authors: Li S,Lepage M,Mérand Y,Bélanger A,Labrie F

    更新日期:1992-01-01 00:00:00

  • Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.

    abstract:PURPOSE:The epithelial-mesenchymal transition (EMT) plays a key role in breast cancer progression and metastasis. Lipocalin 2 (LCN2) is involved in the regulation of EMT. The aim of this study was to investigate the clinicopathological significance of LCN2 expression in breast cancer. METHODS:The expression of LCN2 pr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05488-2

    authors: Kurozumi S,Alsaeed S,Orah N,Miligy IM,Joseph C,Aljohani A,Toss MS,Fujii T,Shirabe K,Green AR,Aleskandarany MA,Rakha EA

    更新日期:2020-02-01 00:00:00

  • Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer.

    abstract::The androgen receptor (AR) is a transcription factor mediating the action of androgens. The AR gene is localized on chromosome X and it contains a series of CAG trinucleotide repeats. The length of the CAG repeats varies among individuals and this polymorphism is believed to be related to AR transcriptional activity. ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006356502820

    authors: Yu H,Bharaj B,Vassilikos EJ,Giai M,Diamandis EP

    更新日期:2000-01-01 00:00:00

  • Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO).

    abstract::Germline mutations in BRCA1/2 confer a high risk of breast cancer (BC), but the magnitude of this risk varies according to various factors. Although controversial, there are data to support the hypothesis of allelic-risk heterogeneity. We assessed variation in BC risk according to the location of mutations recorded in...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1655-3

    authors: Lecarpentier J,Noguès C,Mouret-Fourme E,Stoppa-Lyonnet D,Lasset C,Caron O,Fricker JP,Gladieff L,Faivre L,Sobol H,Gesta P,Frenay M,Luporsi E,Coupier I,GENEPSO.,Lidereau R,Andrieu N

    更新日期:2011-12-01 00:00:00

  • Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.

    abstract::The aim of this study was to evaluate the difference in outcomes based on p53 overexpression of patients with breast cancer who received adjuvant therapy following local treatment for invasive ductal carcinoma, not otherwise specified. We analyzed data from 4,683 patients with cancer enrolled in two institutions betwe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-009-0560-5

    authors: Kim HS,Yom CK,Kim HJ,Lee JW,Sohn JH,Kim JH,Park YL,Ahn SH

    更新日期:2010-06-01 00:00:00

  • Pre-operative axillary ultrasound with fine-needle aspiration cytology performance and predictive factors of false negatives in axillary lymph node involvement in early breast cancer.

    abstract:PURPOSE:Breast cancer is the most common cancer among females worldwide. Axillary lymph node involvement is an important prognostic factor in pre-operative evaluation. The aim of this study was to evaluate the sensitivity and accuracy of AUS during the initial breast cancer diagnosis and the contribution of ultrasound ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05830-z

    authors: Hotton J,Salleron J,Henrot P,Buhler J,Leufflen L,Rauch P,Marchal F

    更新日期:2020-10-01 00:00:00

  • Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities.

    abstract:PURPOSE:The ER-/PR-/HER2- or triple-negative (TNBC) subtype is more prevalent among women who are young, black, Hispanic, and of lower SES. The purpose of this study is to determine if young age and low SES are associated with TNBC within four mutually exclusive race/ethnicities. METHODS:The study identified 19,283 ca...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4159-y

    authors: Parise CA,Caggiano V

    更新日期:2017-05-01 00:00:00

  • Secreted frizzled related protein 2 (sFRP2) decreases susceptibility to UV-induced apoptosis in primary culture of canine mammary gland tumors by NF-kappaB activation or JNK suppression.

    abstract::Tumor formation can result from a decrease in cell death, as well as an increase in cell proliferation. In spite of the high incidence of mammary gland tumors (MGTs) in female dogs, the understanding of its etiology is still poor. Consistent with several proto-oncogenes (such as Wnt) for the mammary gland, sFRP2 is ex...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9233-9

    authors: Lee JL,Chang CJ,Chueh LL,Lin CT

    更新日期:2006-11-01 00:00:00